Prostate Cancer & BPHArchives
Construction of an integrated diagnostic-therapeutic model for prostate cancer using rapid multiplex immunohistochemistry
Prostate Cancer & BPH 1 min.
To explore the feasibility and clinical application value of constructing an integrated model for the diagnosis and treatment of prostate cancer based on rapid multiplex immunohistochemistry (RMI) combined with intraoperative frozen section examination (IFSE). Methods: A total of 50 patients with high...
Salvage stereotactic body radiotherapy for post-prostatectomy recurrence: are we almost there?
Prostate Cancer & BPH 1 min.
The use of hypofractionated radiotherapy (HFRT) after prostatectomy has expanded because of its radiobiological advantages and its potential to reduce treatment burden. Stereotactic body radiotherapy (SBRT), an even more condensed treatment approach, has recently emerged as a possible salvage option...
Phase III randomized studies of mevrometostat and enzalutamide in metastatic prostate cancer (MEVPRO-1 and MEVPRO-2): trial protocols
Prostate Cancer & BPH 1 min.
Phase I investigation of the enhancer of zeste homolog 2 inhibitor, mevrometostat, plus enzalutamide showed promising antitumor activity versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC) (NCT03460977). MEVPRO-1 (open label) and MEVPRO-2 (double blind)...
Novel biomarkers driving treatment selection in metastatic castration-sensitive prostate cancer: fundamentals of personalized clinical decision making
Prostate Cancer & BPH 1 min.
Prostate cancer is well known to be androgen-dependent, with growth directly relying on the androgen receptor signaling pathway. In fact, androgen deprivation therapy, with or without Docetaxel and/or newer hormonal drugs such as Abiraterone acetate, Enzalutamide, Apalutamide, and Darolutamide, remains...
